Asset Details
Do you wish to reserve the book?
HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer
Do you wish to request the book?
HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer
2015
Overview
Background
In the Trastuzumab for GAstric cancer (ToGA) study, trastuzumab plus chemotherapy improved median overall survival by 2.7 months in patients with human epidermal growth factor receptor 2 (HER2)-positive [immunohistochemistry (IHC) 3+/fluorescence in situ hybridization-positive] gastric/gastroesophageal junction cancer compared with chemotherapy alone (hazard ratio 0.74). Post hoc exploratory analyses in patients expressing higher HER2 levels (IHC 2+/fluorescence in situ hybridization-positive or IHC 3+) demonstrated a 4.2-month improvement in median overall survival with trastuzumab (hazard ratio 0.65). The ToGA study provides the largest screening dataset available on HER2 overexpression/amplification in this indication. We further analyzed correlation(s) of HER2 overexpression/amplification with clinical and epidemiological factors.
Methods
HER2-positivity was analyzed by histological subtype, tumor location, geographic region, and specimen type. Exploratory efficacy analyses were performed.
Results
The HER2-positivity rate was 22.1 % across analyzed tumor samples. Rates were similar between European and Asian patients (23.6 % vs. 23.9 %), but higher in intestinal- vs. diffuse-type (31.8 % vs. 6.1 %), and gastroesophageal junction cancer versus gastric tumors (32.2 % vs. 21.4 %). Across all IHC scores, variability in HER2 staining (≤30 % stained cells) was observed in almost 50 % of cases, with increasing rates in lower IHC categories, and did not affect treatment outcome. The polysomy rate was 4 %.
Conclusions
HER2 expression varies by tumor location and type. All patients with advanced gastric or gastroesophageal junction cancer should be tested for HER2 status, preferably using IHC initially. Due to the unique characteristics of gastric cancer, specific testing/scoring guidelines should be adhered to.
Publisher
Springer Japan,Springer Nature B.V
Subject
/ Antineoplastic Combined Chemotherapy Protocols - therapeutic use
/ Esophageal Neoplasms - drug therapy
/ Esophageal Neoplasms - metabolism
/ Esophageal Neoplasms - mortality
/ Esophageal Neoplasms - pathology
/ Esophagogastric Junction - pathology
/ Humans
/ In Situ Hybridization, Fluorescence
/ Medicine
/ Oncology
/ Original
/ Receptor, ErbB-2 - metabolism
/ Stomach Neoplasms - drug therapy
/ Stomach Neoplasms - metabolism
/ Stomach Neoplasms - mortality
/ Stomach Neoplasms - pathology
/ Trastuzumab - administration & dosage
